CanSino Biologics (SHSE:688185) LT-Debt-to-Total-Asset : 0.14 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CanSino Biologics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.14.

CanSino Biologics's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.14). It may suggest that CanSino Biologics is progressively becoming more dependent on debt to grow their business.

CanSino Biologics LT-Debt-to-Total-Asset Historical Data

The historical data trend for CanSino Biologics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics LT-Debt-to-Total-Asset Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.08

0.01

0.02

0.09

0.13

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													-	0.10	0.12	0.13	0.14

CanSino Biologics LT-Debt-to-Total-Asset Calculation

CanSino Biologics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1240.843	/	9318.769
	=	0.13

CanSino Biologics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	1162.688	/	8568.692
	=	0.14

CanSino Biologics (SHSE:688185) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CanSino Biologics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (SHSE:688185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

CASBF:USA 06185:Hong Kong CJH:Germany

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (SHSE:688185) Headlines

No Headlines